In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer

Background and aims: Despite recent advances in advanced prostate cancer treatments, clinical biomarkers or treatments for men with such cancers are imperfect. Targeted therapies have shown promise, but there remain fewer actionable targets in prostate cancer than in other cancers. This work aims to characterise BRD9, currently understudied in prostate cancer, and investigate its co-expression with other genes to assess its potential as a biomarker and therapeutic target in human prostate cancer. Materials and methods: Omics data from a total of 2053 prostate cancer patients across 11 independent datasets were accessed via Cancertool and cBioPortal. mRNA M.expression and co-expression, mutations, amplifications, and deletions were assessed with respect to key clinical parameters including survival, Gleason grade, stage, progression, and treatment. Network and pathway analysis was carried out using Genemania, and heatmaps were constructed using Morpheus. Results: BRD9 is overexpressed in prostate cancer patients, especially those with metastatic disease. BRD9 expression did not differ in patients treated with second generation antiandrogens versus those who were not. BRD9 is co-expressed with many genes in the SWI/SNF and BET complexes, as well as those in common signalling pathways in prostate cancer. Summary and conclusions: BRD9 has potential as a diagnostic and prognostic biomarker in prostate cancer. BRD9 also shows promise as a therapeutic target, particularly in advanced prostate cancer, and as a co-target alongside other genes in the SWI/SNF and BET complexes, and those in common prostate cancer signalling pathways. These promising results highlight the need for wider experimental inhibition and co-targeted inhibition of BRD9 in vitro and in vivo, to build on the limited inhibition data available.

Download Full-text

Brazilian Berry Extract, High‐Fat Diet and Prostate Cancer: In Vitro and In Vivo Evaluation of Inflammation and Extracellular Matrix

The FASEB Journal ◽

10.1096/fasebj.2020.34.s1.09025 ◽

2020 ◽

Vol 34 (S1) ◽

pp. 1-1

Author(s):

Valéria H. Cagnon ◽

Ellen Nogueira Lima ◽

Celina de Almeida Lamas ◽

Andressa Mara Baseggio ◽

Larissa Akemi Kido ◽

...

Keyword(s):

Prostate Cancer ◽

Extracellular Matrix ◽

High Fat Diet ◽

High Fat ◽

In Vivo Evaluation

Download Full-text

In Vitro and In Vivo Evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor-Expressing Prostate Cancer

Journal of Nuclear Medicine ◽

10.2967/jnumed.110.082826 ◽

2011 ◽

Vol 52 (3) ◽

pp. 470-477 ◽

Cited By ~ 46

Author(s):

K. A. Lears ◽

R. Ferdani ◽

K. Liang ◽

A. Zheleznyak ◽

R. Andrews ◽

...

Keyword(s):

Prostate Cancer ◽

In Vivo Evaluation ◽

Peptide Receptor ◽

Gastrin Releasing Peptide

Download Full-text

Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo

Journal of Controlled Release ◽

10.1016/j.jconrel.2020.12.017 ◽

2021 ◽

Vol 330 ◽

pp. 101-110

Author(s):

Maja Severic ◽

Guanglong Ma ◽

Sara G T Pereira ◽

Amalia Ruiz ◽

Calvin C.L. Cheung ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Genetically Engineered

Download Full-text

Targeting the Radiation-Induced ARv7-Mediated circNHS/miR-512-5p/XRCC5 Signaling With Quercetin Signaling Increases Prostate Cancer Radiosensitivity

10.21203/rs.3.rs-659472/v1 ◽

2021 ◽

Author(s):

Dong Chen ◽

Fu-Ju Chou ◽

Yuhchyau Chen ◽

Hao Tian ◽

Yaqin Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Locally Advanced ◽

Radiation Sensitivity ◽

Preclinical Studies ◽

Locally Advanced Prostate Cancer ◽

Radiation Induced ◽

Androgen Receptor Splice Variant

Abstract BackgroundRadiation therapy (RT) with androgen deprivation therapy (ADT) is an effective therapy to suppress the locally advanced prostate cancer (PCa). However, we unexpected found that RT could also inducing the androgen receptor splice variant 7 (ARv7) expression to decrease the radiosensitivity. MethodsThe study was designed to target ARv7 expression with Quercetin or ARv7-shRNA led to enhancing increase the radiation sensitivity to better suppress the PCa that involved the modulating the circNHS/miR-512-5p/XRCC5 signaling.ResultsMechanism studies revealed that RT-induced ARv7 may function via altering the circNHS/miR-512-5p/XRCC5 signaling to decrease the radiosensitivity. Results from preclinical studies using multiple in vitro cell lines and in vivo mouse models concluded that combining RT with small molecule of Quercetin to target full-length AR and ARv7 could lead to better efficacy to suppress PCa progression. ConclusionTogether, these results suggest that ARv7 may play key roles to alter the PCa radiosensitivity, and targeting this newly identified ARv7 mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin may help us to develop a novel RT to better suppress the progression of PCa.

Download Full-text

BRD9 Expression, Alteration, Survival And Pathway Analysis In 11 Independent Prostate Cancer Cohorts

10.20944/preprints202109.0289.v1 ◽

2021 ◽

Author(s):

Nafisa Barma ◽

Timothy C Stone ◽

Lina Maria Carmona Echeverria ◽

Susan Heavey

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Pathway Analysis ◽

Therapeutic Target ◽

Advanced Prostate Cancer ◽

Gleason Grade ◽

Targeted Inhibition ◽

Prostate Cancer Treatments

Background and aims: Despite recent advances in advanced prostate cancer treatments, there are no clinically useful biomarkers or treatments for men with such cancers. Targeted therapies have shown promise, but there remain fewer actionable targets in prostate cancer than in other cancers. This work aims to characterize BRD9, currently understudied in prostate cancer, and investigate its co-expression with other genes to assess its potential as a biomarker and therapeutic target in human prostate cancer. Materials and methods: Omics data from a total of 2053 prostate cancer patients across 11 independent datasets were accessed via Cancertool and cBioPortal. mRNA expression and co-expression, mutations, amplifications, and deletions were assessed with respect to key clinical parameters including survival, Gleason grade, stage, progression and treatment. Network and pathway analysis was carried out using Genemania, and heatmaps were constructed using Morpheus. Results: BRD9 is overexpressed in prostate cancer patients, especially those with metastatic disease. BRD9 expression did not differ in patients treated with second generation antiandrogens versus those who were not. BRD9 is co-expressed with many genes in the SWI/SNF and BET complexes, as well as those in common signaling pathways in prostate cancer. Summary and conclusions: BRD9 has potential as a diagnostic and prognostic biomarker in prostate cancer. BRD9 also shows promise as a therapeutic target, particularly in advanced prostate cancer, and as a co-target alongside other genes in the SWI/SNF and BET complexes, and those in common prostate cancer signalling pathways. These promising results highlight the need for wider experimental inhibition and co-targeted inhibition of BRD9 in vitro and in vivo, to build on the limited inhibition data available.

Download Full-text